10-Year Data from the Medtronic ENGAGE OUS Registry is the First and Only Prospective, Industry Sponsored Global EVAR Registry to Demonstrate a Decade of Durable Outcomes in Real-World Setting

Medtronic today announced its EndurantTM abdominal aortic aneurysm (AAA) stent graft system continues to demonstrate long-term durability through proven outcomes in a real-world setting1. The 10-year Endurant Stent Graft Natural Selection Global post-market registry (ENGAGE) data were presented at the 2023 Charing Cross Symposium in London, marking the completion of the study.

The ENGAGE OUS registry evaluated more than 1,200 patients1. The 10-year data, which included follow-up from approximately 400 of these patients, showed a 94.7 percent freedom from aneurysm-related mortality (ARM) and 64.1 percent sac regression (or decreased AAA sac diameter) at 10 years1.

“Today with the release of the ENGAGE 10-year data, we have achieved a major milestone in EVAR therapy,” said ENGAGE investigator Hence Verhagen, M.D., professor and chief of vascular surgery, Erasmus University Medical Center in Rotterdam, The Netherlands, who presented the data. “There is now strong and robust evidence that patients treated with the Endurant stent graft system are reaching long-term durable outcomes. We can continue to offer the Endurant stent graft system to any of our patients suitable for endovascular repair as the only graft with global, robust, real-world clinical data to 10 years with consistent sac regression and low aneurysm-related mortality.”

At the completion of the study, the ENGAGE registry included patients across 49 sites in 21 countries2. The ENGAGE registry was initiated less than one year post CE mark, further demonstrating the Medtronic confidence in the design of the company’s Endurant system and commitment to long-term clinical excellence. The goal of ENGAGE was to gather evidence in a real-world patient population, including patients with challenging anatomy who have historically been difficult to treat and are associated with limited eligibility for endovascular repair and higher rates of secondary interventions. A thorough monitoring protocol resulted in a clinical follow-up compliance of 89.7 percent and imaging compliance of 68.3 percent at 10-years1.

“As Medtronic works to increase access to treatment for patients with Aortic disease, the 10-year results of the ENGAGE registry demonstrate a critical achievement in the commitment we have made to leading the advancement of EVAR,” said Carolyn Sleeth, vice president and general manager of the Aortic business in Medtronic’s Cardiac and Vascular Group. “These data add to the current evidence showing that the Endurant stent graft system has a decade of proven long-term durable outcomes and allows physicians the opportunity to treat their patients with the most reliable device.”

SourceMedtronic

Hot this week

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”

Avery Dennison Medical Introduces Ipdated SilFoam Lite: Sustainability, MDR Certification & Performance Improvements

The newly enhanced SilFoam Lite delivers superior efficiency and reliability, bringing improved fluid handling capabilities and improved tack. These improvements make the product ideal for customers seeking quality, high-performance solutions in wound care notes Avery Dennison Medical.

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."